Abnormal axonal connectivity and hyperactive mTOR complex 1 (mTORC1) are shared features of several neurological disorders. Hyperactive mTORC1 alters axon length and polarity of hippocampal neurons in vitro, but the impact of hyperactive mTORC1 on axon growth in vivo and the mechanism underlying those effects remain unclear. Using in utero electroporation during corticogenesis, we show that increasing mTORC1 activity accelerates axon growth without multiple axon formation. This was prevented by counteracting mTORC1 signaling through p70S6Ks (S6K1/2) or eIF4E binding protein (4E-BP1/2), which regulate translation. In 
INTRODUCTION
Alterations in long-range cortical connectivity identified using neuroimaging and anatomical methods have been reported in individuals affected by neurodevelopmental disorders associated with hyperactive mTORC1 (1) . Some of the neurological impacts include neurocognitive or psychiatric disorders (2, 3) and epilepsy (4) . Due to the behavioral importance of altered cortical axon connectivity in mTORC1-related disorders, several studies have examined the impact of hyperactive mTORC1 on axon growth. In vitro studies reported that increase in mTORC1 activity leads to abnormal axon polarity, namely multiple axons originating from the soma, and increased total axon length (5-7). These studies either expressed a constitutively active form of Rheb, the canonical activator of mTORC1 (8, 9) , or deleted/knocked down either one of mTORC1's upstream negative regulators Tsc1 or Tsc2, (10) . In an in vivo study, deleting Tsc1 or knocking down Tsc2 during corticogenesis resulted in increased axonal coverage of the cortex based on immunostaining for two axonal markers (SMI-31 or SMI-312) (7) . In addition, the formation of multiple lateral and basal processes was observed in developing cortical pyramidal neurons in embryonic slice cultures following Tsc2 knockdown. However, it is not known whether the multiple processes are indicative of multiple axons since axonal and dendritic markers were not used. It is thus unclear whether neurons form longer and/or multiple axons in vivo in a hyperactive mTORC1 condition during development.
of the most studied functions of mTORC1 (11) . In vitro studies reported that inactivating translation through either constitutive activation of 4E-BP1/2 or knockdown of S6K1/2 was sufficient to prevent axon growth under normal conditions with normal mTORC1 activity (5, 6) .
However, these studies did not examine the contribution of these translational regulators in hyperactive mTORC1 conditions.
We thus set out to determine the impact of hyperactive mTORC1 on axon growth during corticogenesis in vivo and examine downstream players with an emphasis on 4E-BPs and S6Ks.
To do so, we used in utero electroporation to selectively target the anterior cingulate cortex (ACC) and examine axon growth in the contralateral cortex. To increase mTORC1 activity in projection neurons, we transfected cells with a plasmid encoding a constitutively active Rheb (Rheb CA ) (12) (13) (14) . This approach allowed us to identify a consistent increase in axon growth in the hyperactive mTORC1 condition and without the formation of multiple axons. We also found that blocking translation by manipulating either 4E-BP1/2 or S6K1/2 was sufficient to prevent mTORC1-induced accelerated axon growth. In addition to translational regulation, S6K1/2 has additional functions through the phosphorylation of several downstream targets (15, 16) . In particular, hyperactive mTORC1-S6K1 has been shown to directly and indirectly alter the phosphorylation level of GSK3β (17) (18) (19) , a known regulator of axonal polarity (for reviews see (20) (21) (22) ). However, it is unknown whether hyperactive mTORC1-S6K1 alters the activity of GSK3β and whether the alteration subsequently contributes to axonal defects. Because of inconsistent experimental effects of GSK3β on normal axon growth in vitro and in vivo and the level of GSK3β activity under hyperactive mTORC1-S6K1, we examined the level of GSK3β phosphorylation and activity as well as its role in axon growth under normal and hyperactive mTORC1 conditions. We found that GSK3β exhibited increased activity in vitro and in vivo with hyperactive mTORC1. In addition, blocking GSK3β function in vivo prevented the accelerated axon growth induced by hyperactive mTORC1 while having no effect on physiological axon growth.
These data suggest that accelerated axon growth during cortical development can be prevented by either decreasing cap-dependent translation through 4E-BP or reducing GSK3β activity in disorders associated with upregulated TSC-Rheb-mTORC1 signaling. Remarkably, blocking one of the multiple effectors downstream of mTORC1 is sufficient to prevent abnormal axon growth providing novel strategies to rescue long-range connectivity defects in neurodevelopmental mTORopathies.
RESULTS

Focally increasing mTORC1 activity led to accelerated axon growth without altering neuronal polarity in vivo
To examine the impact of increased mTORC1 activity on axonal growth in cortical neurons in vivo, we expressed a DNA plasmid encoding constitutively active Rheb (Rheb CA ), the canonical activator of mTORC1, using in utero electroporation (Fig. 1A inset) . We and others reported that Rheb CA expression allows rapid activation of mTORC1 in vitro and in vivo (13, 14, 23, 24) . We targeted the anterior cingulate cortex (ACC) because this region is routinely affected in individuals with TSC and other neurocognitive disorders (25, 26) , and it allows for reproducible and accurate axon visualization (Fig. 1A) . Electroporation at embryonic day (E) 15 resulted in plasmid expression in layer 2/3 pyramidal neurons that project axons to the contralateral cortex.
The targeted neurons were visualized by co-transfection of a plasmid expressing tdTomato (Fig. axons in coronal slices from postnatal day (P) 0 animals revealed that Rheb CA accelerated axon growth (Fig. 1A) . Because the number of cells targeted by electroporation, we analyzed sections with equal electroporation efficiency (see Methods). We found that the length of the longest axons in white and grey matter was significantly increased by 2.5-and 3.6-fold, respectively (statistics and N are provided in figure legends, Fig. 1B and C) . In addition, axons had entered the grey matter in the contralateral cortex in only 5/12 of the control mice compared to all of the mice (11/11) (Fig. 1D ). Processes were identified as axons by ankyrin G immunostaining at P8 and Z-stack imaging was performed to fully examine neurons in three-dimensions. The lack of multiple axon formation in Rheb CA -expressing neurons was confirmed in 2 month-old animals (Fig. S1) . Thus, increased mTORC1 activity during development leads to accelerated axon growth without change in polarity (i.e., axon number and direction). significantly accelerated axon growth compared to those transfected with BFP ( Fig. 2A and B) .
Culturing neurons in the presence of 100 nM rapamycin for 4 days (beginning 4 hours after plating) led to a significant decrease in axon length and normalizes the length of Rheb CA -expressing axons ( Fig. 2C and D) . shown to prevent axon growth under normal conditions in vitro (5, 6) . However, it remains unknown whether manipulating these pathways is sufficient to prevent accelerated growth under hyperactive mTORC1 condition considering the many molecular targets of mTORC1.
To explore the contribution of 4E-BPs, we employed an mTOR-resistant, constitutively active 4E-BP1 plasmid (4E-BP1 CA ) (Fig. 3A) , which constitutively binds eukaryotic initiation factor 4E (eIF4E) and therefore mimics the effects of all endogenous 4E-BPs (28 (Fig. 3B) . Co-electroporation of 4E-BP1 CA with Rheb CA prevented accelerated axon growth induced by hyperactive mTORC1 in vivo (Fig. 3C, D , and E).
To assess the role of S6K1/2, we used a dominant negative S6K1 (S6K1 DN , K100R (29)) in vitro, and we also knocked down S6K1/S6K2 using a vector expressing an shRNA against both S6K1 and S6K2 in vivo (Fig. 4A) S2) . We previously validated this shRNA both in vivo and in vitro (14) . Co-electroporation of S6K1 DN with Rheb CA normalized axon length in vitro (Fig. 4B) . Similarly, co-electroporation of S6K1/2 shRNA with Rheb CA fully normalizes accelerated axon growth induced by hyperactive mTORC1 in vivo ( Fig. 4C-E) .
Collectively, these data suggest that enhancing 4E-BP1/2 activity or blocking S6K1/2 activity is sufficient to normalize the accelerated axon growth in vivo that was caused by hyperactive mTORC1. Considering that 4E-BP1/2 is only known to act as a cap-dependent translational repressor, these data suggest that increased cap-dependent translation is necessary for allowing accelerated axon growth induced by hyperactive mTORC1. On the other hand, in addition to regulating translation, S6K1/2 phosphorylates and thus regulates the activity of many targets involved in other cellular processes. One of these downstream pathways, which signals to the well-known regulator of axon development GSK3β, is explored in the next section.
GSK3β activity is increased in hyperactive mTORC1 condition
Hyperactive mTORC1-S6K1/2 is known to indirectly decrease AKT activity and thus GSK3β phosphorylation (at serine [Ser] 9) as part of a negative homeostatic feedback (17, 18) . Direct phosphorylation of GSK3β by S6K1 has also been reported in Tsc2 null immortalized cells (19) .
Thus, to examine GSK3β phosphorylation level in Rheb CA condition, we transfected cortical neurons in vitro with Rheb CA or BFP (control) and performed immunoblotting analysis. We found increased phospho-S6 (Ser240/244) and decreased phospho-AKT (Ser473) and phospho- 
GSK3β does not regulate axon growth during later corticogenesis under physiological condition
GSK3β has been implicated in the regulation of axon growth, but the function of GSK3β on axon growth in vitro and in vivo remains unclear due to inconsistent findings in previous studies (for reviews see (20) (21) (22) ). We thus examined the impact of either increasing or blocking GSK3β activity on axon growth in vitro and in vivo using constitutively active and dominant negative GSK3β mutants (GSK3β CA S9A and GSK3β DN K85M/K86I (32)), which have previously been used by others. We first validated the efficiency of these vectors in Neuro2a cells. In Neuro2a cells, GSK3β DN significantly increased phospho-GSK3β level and decreased phosphorylation of the GSK3β target, CRMP2 (Thr514) indicating decreased GSK3β activity ( Fig. S4A -C).
GSK3β
CA had the opposite effect, as expected ( Fig. S4A-C) .
Next, primary cortical neurons were transfected with either GSK3β CA or GSK3β DN and tdTomato. GSK3β CA had no effect on axon growth in vitro while GSK3β DN decreased axon length by 40% ( Fig. 6A and B) . In vivo neither GSK3β CA nor GSK3β DN had any effect on axon growth ( Fig. 6C-E) . These data suggest that in vitro GSK3β is activated and contributes to axon growth, but additional activation of GSK3β above baseline does not further increase axon growth. In vivo, GSK3β does not appear to regulate the elongation of cortical axons as neither vector had any effect on axon length. These in vivo data are consistent with those in the GSK3β-S9A knock-in mice (33) and GSK3α-S21A/GSK3β-S9A double knock-in mice as well as in the Decreasing GSK3β activity in vitro and in vivo prevents accelerated axon growth resulting in a significant reduction in abnormal axon length although not completely back to control level in the grey matter ( Fig. 7D and E) . We and others previously reported that a focal increase in mTORC1 activity during development leads to neuronal misplacement across cortical layers (35) (36) (37) . We thus examined placement of Rheb CA -expressing neurons in coronal sections at P8 when migration of electroporated neurons to layer 2/3 is almost complete. Rheb CA expression at E15 led to cell scattering across cortical layers in coronal sections at P8 as well as the formation of white matter heterotopia (Fig. 7F) . GSK3β DN did not prevent neuronal misplacement or white matter heterotopia induced by Rheb CA (Fig. 7F and G) . These data highlight a remarkable selectivity for GSK3β in normalizing axon elongation but not neuronal misplacement in hyperactive mTORC1 condition.
Next, we examined whether pharmacologically blocking GSK3β activity in vitro and in vivo would prevent Rheb CA -induced accelerated axon growth. In vitro, we used two wellestablished pharmacological GSK3β blockers, AR-A014418 and lithium chloride (38, 39) . In cultured cortical neurons transfected with tdTomato, AR-A014418 (20 µM) and lithium (2 mM) prevented accelerated axon growth in the Rheb CA condition (Fig. 8A-C) . Finally, we examined whether LiCl injections in vivo (600 mM, every day from E15 to E19, Fig. 8E ) would rescue the Rheb CA -induced axonal defect in vivo. LiCl significantly prevented the accelerated axon growth in both the grey and white matter (Fig. 8D, F, and G) .
DISCUSSION
In this study, we focused on determining the function of hyperactive mTORC1 on axon growth during late corticogenesis and identifying downstream players that mediate mTORC1's effects.
Our findings are summarized in Figure 9 .
Our data reveal that hyperactive mTORC1 during late corticogenesis leads to accelerated axon growth, but mTORC1-high neurons form one single axon contrary to previous in vitro studies using hippocampal neurons (5-7). An increase in axon length was expected based on previous studies reporting that genetically increasing mTORC1 activity leads to increased axon length in vitro and increased axonal tract in vivo (7, 40) . In addition, mTORC1 activation following injury improves axonal regeneration in vivo (41) (42) (43) . The lack of multiple axon formation in vivo may be explained by a difference between an in vitro and an in vivo setting and between regions (hippocampus versus cortex).
Next, in order to identify mTORC1 effectors of axon growth, we focused on 4E-BPs and S6Ks. Co-electroporation of either a constitutively active 4E-BP or an shRNA against S6K1/2 was sufficient to prevent hyperactive mTORC1-induced accelerated axon growth. Considering that 4E-BPs only reported function is the regulation of cap-dependent translation and we previously reported that the 4E-BP1 CA vector used here normalized Rheb CA -induced increase in translation in vivo, our data suggest that normalizing cap-dependent translation is sufficient to prevent accelerated axon growth in hyperactive mTORC1 condition.
In addition to regulating translation, S6Ks have a multitude of targets (15, 16) . In particular, under hyperactive mTORC1 condition S6K1 is part of a negative homeostatic feedback leading to decreased IRS-1 and AKT phosphorylation (for reviews see (44) (45) (46) ).
Consistent with this feedback, two studies using conditional Tsc1 knockout mice reported decreased AKT phosphorylation resulting in decreased GSK3β S9 phosphorylation (17, 18, 47) .
Our data in Rheb CA -expressing neurons in vitro as well as conditional Tsc1 cKO cortex are in agreement with these published data. However, another elegant study suggested that in a Tsc2 null condition (in immortalized mouse embryonic fibroblasts cells) S6K1 could directly phosphorylate GSK3β and thus lead to hyperphosphorylation of GSK3β (19) . The discrepancy between these results is presumably due to the different cell types used. Here, we also found that a GSK3β target, MAP1B, was hyperphosphorylated in Rheb CA -expressing cortical neurons in vitro consistent with decreased GSK3β S9 phosphorylation and increased kinase activity.
Considering that GSK3β can regulate axon growth in development (for reviews see (20) (21) (22) ), we investigated the impact of GSK3β on accelerated axon growth in our system and condition. We first explored the impact of activating or blocking GSK3β activity on normal axon growth since previously published findings have been inconsistent. Indeed, some studies suggest that suppression of GSK3β activity in vitro is required for the formation of multiple axons and axon elongation (33, 34, 48, 49, (49) (50) (51) (52) (53) (54) (55) while others show that GSK3β inhibition prevents axon extension (52, (56) (57) (58) . To reconcile these inconsistent data, it has been suggested that the final outcome of GSK3β inhibition is dependent on the extent and timing of GSK3β inhibition and the downstream substrates involved (20, 51, 52) . Here, in cultured Rheb CA -expressing cortical neurons, constitutive activation of GSK3β (using a Ser9 to Ala9 substitution in GSK3β) did not alter axon elongation while blocking GSK3β activity with a dominant negative mutant decreased axon elongation. In vivo transgenic mice expressing constitutively active GSK3β and GSK3α
(knockin mice) and GSK3β knockout mice do not display any gross axonal defects (33, 34, 51) . In our condition, neither the constitutively active nor the dominant negative GSK3β altered axon growth in vivo consistent with some findings in previous in vivo studies using transgenic mice (33, 34) . These data suggest that GSK3β activation alone through phosphorylation at Ser9 is not sufficient for altering axon growth and may thus require activation of additional pathways or molecules. Similarly, the lack of effect of blocking GSK3β activity on axon growth during corticogenesis suggests that either GSK3β is not activated or GSK3α compensated for the loss of GSK3β activity. However, data from the Rheb CA condition, in which blocking GSK3β activity is sufficient to prevent accelerated axon growth, suggest that GSK3α is not compensating in this condition. The fact that blocking GSK3β activity does not alter axon growth under normal conditions also suggests that the effect of the dominant negative GSK3β in the Rheb CA condition is due to normalizing GSK3β activity increased by hyperactive mTORC1.
In conclusion, developing and adult cortical neurons expressing hyperactive mTORC1 displayed longer axons and a single axon projecting towards the white matter. The increase in axon length that we observe could lead to a premature increase in inter-cortical axonal connectivity that is expected to impair circuit formation and lead to abnormal network function in adults (59) . We also report that blocking GSK3 β signaling or cap-dependent translation through 4E-BPs or S6K1/2 in developing neurons limited hyperactive mTORC1-induced accelerated axonal elongation in vivo. These data suggest that increased GSK3β activity is required for axon overgrowth in vivo in the context of increased mTORC1 activity. Collectively, our findings offer additional molecular targets to limit axonal defects in TSC-mTORC1-related developmental disorders leading to epilepsy and neurocognitive or psychiatric deficits such as tuberous sclerosis complex and focal cortical dysplasia (60,61) as well as acquired epilepsy associated with mTORC1-dependent axonal sprouting (62) . Brain fixation and immunofluorescence: P0 mouse brains were dissected and drop-fixed in 4%
MATERIALS AND METHODS
Animals and genotyping:
paraformaldehyde overnight before being embedding in 3% agarose. Brains were sectioned coronally at a thickness of 150 µm on a vibratome (Leica VT1000).
For Ankyrin G immunostaining, brains of P8 and 2 month-old mice were perfused transcardially with 4% formaldehyde, cryoprotected with 30% sucrose, embedded in OCT compound (Tissue Tek), and sectioned at 100 μm using a microtome. Free-floating sections were incubated for 1 hour in a blocking solution (2% bovine serum albumin and 0.3% Triton-X in PBS) at room temperature and then incubated with anti-ankyrin G (NeuroMab, 1:1000) overnight at 4ºC. Sections were washed with PBS and then placed in blocking solution containing secondary antibodies (Alexa Fluor conjugated, Molecular Probes, 1:1000) for 1 hour at room temperature. All images were taken using an FV1000 confocal microscope (Olympus).
Culture of embryonic cortical neurons followed by nucleofection: The cortices of E16 pups were dissected out, incubated in papain (Worthington) for 15 min at 37°C and dissociated by pipetting in plating medium (MEM supplemented with 5% fetal calf serum, 0.6% Glucose, 2 mM Glumax). Following dissociation, cells were nucleofected using a Mouse Neuron
Nucleofector kit VPG-1001 (Lonza; 3-5 µg DNA was transfected in 4x10 6 cells following the manufacture instructions. Cells were then resuspended cells in MEM supplemented with 0.6% glucose and 5% FBS and plated on poly-D-lysine-coated coverslips. The medium was changed to neuronal maintenance media (neurobasal medium medium with 1X B27 and 1X GlutaMAX-1) 1-2 hours after plating. Half of the medium was then changed every three days. Neurons were plated at a higher density (1x10 6 cells per well) for western blot and lower density (30-50,000 cells per coverslip) for immunostaining. Western blot and immunostaining were performed 6 and 4 days after plating, respectively. Neurons cultured on coverslips were fixed using 4% paraformaldehyde for 15 min and then incubated with primary antibody followed by the appropriate secondary antibody. Lithium (Sigma) and AR-A014418 (Sigma) was added to neuronal maintenance media 4 hours after initial medium change.
Neuro2a cell culture and transfection:
The Neuro2a mouse neuroblastoma cells were propagated using standard protocol and transfected with Polyjet (SignaGen Laboratories) at 80%
confluence. Protein was harvested 48 or 72 hours after transfection.
Western blots from mice, Neuro2a cells, and nucleofected neurons: Neuro2a cells and neurons cultured for 6 days were lysed on ice using a lysis buffer consisting of RIPA buffer, 1X
Halt protease and phosphatase inhibitor (Thermo Scientific), 5 mM EDTA and 20 units/ml DNase I (Roche). Lysates were cleared by spinning at 12,000 rcf for 10 minutes and then boiled with Laemmli sample buffer for 5 minutes. Lysates were run on 4-15% tris-glycine gradient gels (Bio-rad, 456-1086) and transferred to PVDF membranes. Membranes were then placed in blocking buffer (5% milk or 5% BSA in TBS+0.1% Tween 20) for 1 hour at room temperature, followed by incubation with primary antibody in blocking buffer overnight at 4 o C. Membranes were washed with TBS + 0.1% Tween 20 before another blocking buffer incubation followed by secondary antibody incubation at room temperature for 1 hour. Antibodies are listed in Table S1 .
Quantifications were performed using NIH Image J software. Measurements were normalized to ERK as a loading control. For the phosphorylated form of proteins, data were normalized to the total levels from the same PVDF membrane.
Quantification of axon length in vivo and in vitro, and cell misplacement: Images of tdTomato+ axons were acquired in cultures or 150 and 100 µm-thick coronal sections for axon length and misplacement analysis, respectively, using a Fluoview 1000 confocal microscope with a 20X or 10X objective. The length of the longest axon was measured both in vitro and in vivo because this was the most straightforward method and was similar to the one used in vitro by many others. In vivo the axon length was measured from the midline to the tip of the longest axon. In addition, Z-stack images were acquired with the 20X objective (with 2X zoom) focusing at the tip of the axons to detect the longest axon. We measured in 2-4 consecutive sections per mouse and in N>3 mice per condition because the longest axons could be cut in a single section.
Axon length was measured using ImageJ at P0.
Cell misplacement was analyzed in P8 sections. The cortex was partitioned into 10 bins.
Bins were evenly spaced from the pial surface to the white matter, with bin 1 being the most superficial. The number of tdTomato+ cells in each bin was counted using the Cell Counter plugin for ImageJ. Only cells within the gray matter of the cortex were quantified.
All analyses were performed in sections with similar electroporation efficiency. To assess efficiency, the fluorescence intensity of the electroporated ACC was assessed in Image J to yield a mean ± standard deviation (SD) using sections shown in Figure 1 . Every image was taken using a high-low filter to equalize fluorescence emission between sections. We analyzed axon length in sections that displayed a fluorescence intensity in the range of mean +/-SD.
Drugs: AR-A014418 and lithium chloride were from Sigma-Aldrich. Rapamycin was from A.G.
Scientific. All three drugs were dissolved in DMSO (vehicle) for in vitro experiments and control cells were treated with similar concentrations of DMSO. For in vivo drug treatment, intraperitoneal injections of 600 mM LiCl or NaCl (10 μl/g body weight, saline) was performed every day from E15 after electroporation to E19 (66) .
Statistics: N indicates the number of animals in each condition or the number of culture set.
Data were plotted in GraphPad Prism 6. Statistical significance was determined using unpaired two-tailed Student's t-test or one way ANOVA with Tukey post-hoc, or two way repeated measures ANOVA with p<0.05 for significance. Data are presented as mean ± SEM. 
